Ballal Rahul D. — SEC Form 4 filings
SEC reporting owner CIK 1805097. 16 Form 4 filings on record with FilingPulse; latest filed 2026-06-23.
Transaction summary — filings shown
Covers all 16 filings on record, filed 2024-02-15 to 2026-06-23. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 13 legs across 6 filings — 117,420 shares, $3,358,466 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 42.
- Largest priced transaction: sale of 30,300 shares @ $23.14 ($701,024) in Enliven Therapeutics, Inc., filed 2024-04-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | Director | 9 | — | 8 legs · 97,420 sh · $2,241,320 | 22 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | Director | 7 | — | 5 legs · 20,000 sh · $1,117,147 | 20 |
Form 4 filings — Ballal Rahul D.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-23 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 2,816 @ $0 · Option exercise (M): 2,816 (derivative) @ $0 · Grant/award (A): 2,927 (derivative) @ $0 · Grant/award (A): 14,950 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 17,126 (derivative) @ $0 | EDGAR |
| 2025-08-13 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 2,302 @ $0 · Option exercise (M): 2,302 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 2,120 @ $0 · Grant/award (A): 2,816 (derivative) @ $0 · Grant/award (A): 15,768 (derivative) @ $0 · Option exercise (M): 2,120 (derivative) @ $0 | EDGAR |
| 2025-02-10 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 20,491 (derivative) @ $0 | EDGAR |
| 2024-11-12 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 10,000 @ $25.99 · Sale (S): 8,132 @ $53.32 · Sale (S): 1,868 @ $54.41 · Option exercise (M): 10,000 @ $25.99 · Sale (S): 3,571 @ $57.24 · Sale (S): 4,929 @ $58.57 · +3 more | EDGAR |
| 2024-10-10 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 6,314 @ $19.68 · Option exercise (M): 4,106 @ $5.52 · Sale (S): 10,420 @ $28.17 · Option exercise (M): 6,314 (derivative) @ $0 · Option exercise (M): 4,106 (derivative) @ $0 | EDGAR |
| 2024-08-13 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 2,302 @ $0 · Option exercise (M): 2,302 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Grant/award (A): 2,120 (derivative) @ $0 · Grant/award (A): 11,774 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 3,388 @ $0 · Option exercise (M): 3,388 (derivative) @ $0 | EDGAR |
| 2024-04-12 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 13,600 @ $12.60 · Sale (S): 13,600 @ $21.01 · Option exercise (M): 48,820 @ $12.60 · Option exercise (M): 4,580 @ $19.68 · Sale (S): 30,300 @ $23.14 · Sale (S): 20,032 @ $25.00 · +4 more | EDGAR |
| 2024-04-08 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 3,485 @ $12.60 · Sale (S): 3,485 @ $19.15 · Option exercise (M): 3,485 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 94 @ $12.60 · Option exercise (M): 3,143 @ $5.52 · Sale (S): 3,237 @ $19.08 · Option exercise (M): 94 (derivative) @ $0 · Option exercise (M): 3,143 (derivative) @ $0 | EDGAR |
| 2024-03-22 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 13,278 @ $5.52 · Sale (S): 13,278 @ $19.16 · Option exercise (M): 13,278 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4/A | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 23,364 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 16,835 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1805097 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →